Office of Technology Management
University Center Tower (UCT)
7000 Fannin Street, Suite 720
Houston, Texas 77030
Phone: (+1) 713-500-3369
Fax: (+1) 713-500-0331
MULTI-FUNCTIONAL LINKING AGENT FOR IMAGING AND THERAPY Imaging technologies are uniquely positioned to enhance how localized and metastatic tumors are treated. In cases where surgery is indicated, a novel class of imaging agents which combine radioactive of fluorescent tags can be used to improve tumor visualization in real-time. When cancer has spread throughout the body, a cytotoxic compound can be combined with radioactive label to develop a “theranostic” method to see and treat disease. Tumor-specificity is critical to the success of these approaches and investigators at T...
Bruxnostic ApplianceBruxism is a significant concern for restorative dentists and orofacial pain practitioners. Consequences of bruxism, if not addressed, can range from minor annoying tooth sensitivity, chronic pain and discomfort, to destruction of dentition and loss of masticatory function. Bruxism is excessive teeth grinding or jaw clenching considered being an oral parafunctional activity. According to relevant literature, its prevalence ranges from 8–31% in the general population according to some studies, while other studies estimated only 10% of the population. Symptoms commonly ...
Background:Every year, more than 1 in 10 babies are born prematurely, before 37 weeks of pregnancy. Complications resulting from preterm birth is the leading cause of death in children under 5 years of age, and the rate of preterm birth has increased steadily in the past decades. Preterm birth due to preterm labor continues to be a challenging concern for the practicing obstetrician. Very few drugs have been proven to be effective in the treatment of preterm labor to improve neonatal outcomes. Unfortunately, tocolytic modalities that have shown to be effective are often limited in ...
• Science2Startup - A Biotech Entrepreneurship Event to Foster Therapeutic Startups
Application Deadline: November 15, 2017
Science2Startup is an invitation-only event for biotech entrepreneurship co-organized by Atlas Venture, F-Prime Capital and SV Health Investors that will build connectivity across the academic, tech transfer, and venture capital communities. This one-day symposium on April 24, 2018 in Cambridge, MA will feature presentations and posters from top therapeutics researchers to a curated audience of experienced biotech venture capitalists, entrepreneurs at leading biotech startups, and senior executives at large pharma companies. Learn more